Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of pomalidomide-based regimens in high-risk newly diagnosed and relapsed/refractory multiple myeloma
ChiCTR2100050710Phase 4Recruiting
- Sponsor
- Anqing Municipal Hospital
- Start
- Oct 2021
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pomalidomide in multiple myeloma (MM), sponsored by Anqing Municipal Hospital. Primary endpoint: Overall response rate. Started Oct 2021; status: recruiting.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2100050710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050710.